Translated fromCroatian1. Antagonističko humanizirano ili kimerno monoklonsko protutijelo ili njegov fragment koji veže antigen sposoban specifično vezati ljudski TNFR2, naznačeno time, da protutijelo ili njegov fragment koji veže antigen sadrži sljedeće regije koje određuju komplementarnost (CDR):(a) CDR-H1 koja sadrži aminokiselinsku sekvencu GFTFSSY (identifikacijski broj sekvence: 23);(b) CDR-H2 koja sadrži aminokiselinsku sekvencu SSGGSY (identifikacijski broj sekvence: 24);(c) CDR-H3 koja sadrži aminokiselinsku sekvencu QRVDGYSSYWYFDV (identifikacijski broj sekvence: 25);(d) CDR-L1 koja sadrži aminokiselinsku sekvencu SASSSVYYMY (identifikacijski broj sekvence: 26)(e) CDR-L2 koja sadrži aminokiselinsku sekvencu STSNLAS (identifikacijski broj sekvence: 27); i(f) CDR-L3 koja sadrži aminokiselinsku sekvencu QQRRNYPYT (identifikacijski broj sekvence: 28);ili pri čemu protutijelo ili njegov i fragment koji veže antigen sadrži sljedeće CDR regije:(g) CDR-H1 koja sadrži aminokiselinsku sekvencu GYTFTDYL (identifikacijski broj sekvence: 274);(h) CDR-H2 koja sadrži aminokiselinsku sekvencu VDPEYGST (identifikacijski broj sekvence: 258);(i) CDR-H3 koja sadrži aminokiselinsku sekvencu ARDDGSYSPFDYWG (identifikacijski broj sekvence: 259);(j) CDR-L1 koja sadrži aminokiselinsku sekvencu QNINKY (identifikacijski broj sekvence: 260)(k) CDR-L2 koja sadrži aminokiselinsku sekvencu YTS; i(I) CDR-L3 koja sadrži aminokiselinsku sekvencu CLQYVNLIT (identifikacijski broj sekvence: 273).1. Antagonistic humanized or chimeric monoclonal antibody or antigen-binding fragment thereof capable of specifically binding human TNFR2, characterized in that the antibody or antigen-binding fragment thereof contains the following complementarity determining regions (CDRs):(a) CDR-H1 containing the amino acid sequence GFTFSSY (SEQ ID NO: 23);(b) CDR-H2 containing the amino acid sequence SSGGSY (SEQ ID NO: 24);(c) CDR-H3 containing the amino acid sequence QRVDGYSSYWYFDV (SEQ ID NO: 25);(d) CDR-L1 containing the amino acid sequence SASSSVYYMY (SEQ ID NO: 26)(e) CDR-L2 comprising the amino acid sequence STSNLAS (SEQ ID NO: 27); and(f) CDR-L3 containing the amino acid sequence QQRRNYPYT (SEQ ID NO: 28);or wherein the antibody or antigen-binding fragment thereof contains the following CDR regions:(g) CDR-H1 containing the amino acid sequence GYTFTDYL (SEQ ID NO: 274);(h) CDR-H2 comprising the amino acid sequence VDPEYGST (SEQ ID NO: 258);(i) CDR-H3 comprising the amino acid sequence ARDDGSYSPFDYWG (SEQ ID NO: 259);(j) CDR-L1 containing the amino acid sequence QNINKY (SEQ ID NO: 260)(k) CDR-L2 comprising the amino acid sequence YTS; and(I) CDR-L3 containing the amino acid sequence CLQYVNLIT (SEQ ID NO: 273).2. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da:(a) CDR-H1 sadrži aminokiselinsku sekvencu GFTFSSY (identifikacijski broj sekvence: 23);(b) CDR-H2 sadrži aminokiselinsku sekvencu SSGGSY (identifikacijski broj sekvence: 24);(c) CDR-H3 sadrži aminokiselinsku sekvencu QRVDGYSSYWYFDV (identifikacijski broj sekvence: 25);(d) CDR-L1 sadrži aminokiselinsku sekvencu SASSSVYYMY (identifikacijski broj sekvence: 26)(e) CDR-L2 sadrži aminokiselinsku sekvencu STSNLAS (identifikacijski broj sekvence: 27); i(f) CDR-L3 sadrži aminokiselinsku sekvencu QQRRNYPYT (identifikacijski broj sekvence: 28).2. The antibody or its antigen-binding fragment according to patent claim 1, characterized in that:(a) CDR-H1 contains the amino acid sequence GFTFSSY (SEQ ID NO: 23);(b) CDR-H2 contains the amino acid sequence SSGGSY (SEQ ID NO: 24);(c) CDR-H3 contains the amino acid sequence QRVDGYSSYWYFDV (SEQ ID NO: 25);(d) CDR-L1 contains the amino acid sequence SASSSVYYMY (SEQ ID NO: 26)(e) CDR-L2 comprises the amino acid sequence STSNLAS (SEQ ID NO: 27); and(f) CDR-L3 contains the amino acid sequence QQRRNYPYT (SEQ ID NO: 28).3. Protutijelo ili njegov fragment koji veže antigen prema patentnom zahtjevu 1, naznačeno time, da:(a) CDR-H1 sadrži aminokiselinsku sekvencu GYTFTDYL (identifikacijski broj sekvence: 274);(b) CDR-H2 sadrži aminokiselinsku sekvencu VDPEYGST (identifikacijski broj sekvence: 258);(c) CDR-H3 sadrži aminokiselinsku sekvencu ARDDGSYSPFDYWG (identifikacijski broj sekvence: 259);(d) CDR-L1 sadrži aminokiselinsku sekvencu QNINKY (identifikacijski broj sekvence: 260)(e) CDR-L2 sadrži aminokiselinsku sekvencu YTS; i(f) CDR-L3 sadrži aminokiselinsku sekvencu CLQYVNLIT (identifikacijski broj sekvence: 273).3. The antibody or its antigen-binding fragment according to patent claim 1, characterized in that:(a) CDR-H1 contains the amino acid sequence GYTFTDYL (SEQ ID NO: 274);(b) CDR-H2 contains the amino acid sequence VDPEYGST (SEQ ID NO: 258);(c) CDR-H3 comprises the amino acid sequence ARDDGSYSPFDYWG (SEQ ID NO: 259);(d) CDR-L1 contains the amino acid sequence QNINKY (SEQ ID NO: 260)(e) CDR-L2 comprises the amino acid sequence YTS; and(f) CDR-L3 contains the amino acid sequence CLQYVNLIT (SEQ ID NO: 273).4. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 – 3, naznačeno time, da navedeno protutijelo ili njegov fragment fragment koji veže antigen:(a) je odabrano iz skupine koja se sastoji od primarnog protutijela ili njegovog fragmenta koji veže antigen, bispecifičnog protutijela ili njegovog fragmenta koji veže antigen, multispecifičnog protutijela ili njegovog fragmenta koji veže antigen, dualno-varijabilne imunoglobulinske domene, monovalentnog protutijela ili njegovog fragmenta, jednolančane Fv molekule (scFv), dijatijela, triatjela, proteinske strukture slične protutijelu, Fv fragmenta, Fab fragmenta, F(ab')2 molekule i tandema scFv (taFv), opcijski naznačeno time, da navedeno protutijelo ili njegov fragment koji veže antigen je molekula F(ab')2;(b) sadrži izotip odabran iz skupine koju čine IgG, IgA, IgM, IgD i IgE;(c) je konjugirano s terapeutskim sredstvom, po mogućnosti naznačeno time, da navedeno terapeutsko sredstvo je citotoksično sredstvo; i/ili(d) je jednolančani polipeptid.4. Antibody or antigen-binding fragment thereof according to any of claims 1-3, characterized in that said antibody or antigen-binding fragment thereof:(a) is selected from the group consisting of a primary antibody or an antigen-binding fragment thereof, a bispecific antibody or an antigen-binding fragment thereof, a multispecific antibody or an antigen-binding fragment thereof, a dual-variable immunoglobulin domain, a monovalent antibody or a fragment thereof, single-chain Fv molecules (scFv), dibodies, tribodies, antibody-like protein structures, Fv fragments, Fab fragments, F(ab')2 molecules and tandem scFv (taFv), optionally indicated by the fact that said antibody or antigen-binding fragment thereof is molecule F(ab')2;(b) contains an isotype selected from the group consisting of IgG, IgA, IgM, IgD and IgE;(c) is conjugated to a therapeutic agent, preferably indicated that said therapeutic agent is a cytotoxic agent; and/or(d) is a single chain polypeptide.5. Konstrukt koji sadrži prvu polipeptidnu domenu i drugu polipeptidnu domenu, naznačen time, da navedena prva polipeptidna domena i navedena druga polipeptidna domena svaka neovisno sadrže jednolančani polipeptid prema patentnom zahtjevu 4 (d) i naznačen time, da navedenom konstruktu nedostaje mišja Fc domena, opcijski naznačen time, da su navedena prva polipeptidna domena i navedena druga polipeptidna domena vezane kovalentnom vezom, po mogućnosti naznačen time, da navedena kovalentna veza sadrži amidnu vezu ili disulfidnu vezu.5. A construct containing a first polypeptide domain and a second polypeptide domain, characterized in that said first polypeptide domain and said second polypeptide domain each independently contain a single-chain polypeptide according to claim 4 (d) and characterized in that said construct lacks a mouse Fc domain, optionally characterized in that said first polypeptide domain and said second polypeptide domain are linked by a covalent bond, preferably indicated in that said covalent bond contains an amide bond or a disulfide bond.6. Polinukleotid koji kodira protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 – 4 ili konstrukt prema patentnom zahtjevu 5.6. A polynucleotide encoding an antibody or an antigen-binding fragment thereof according to any of claims 1-4 or a construct according to claim 5.7. Vektor koji sadrži polinukleotid prema patentnom zahtjevu 6, opcijski naznačen time, da:(a) navedeni vektor je ekspresijski vektor, opcijski naznačen time, da navedeni ekspresijski vektor je eukariotski ekspresijski vektor; ili(b) navedeni vektor je virusni vektor, opcijski naznačen time, da je navedeni virusni vektor odabran iz skupine koju čine adenovirus (Ad), retrovirus, poksvirus, adenoasocirani virus, bakulovirus, herpes simplex virus i virus vakcinije, opcijski naznačen time, da navedeni adenovirus je adenovirus serotipa 5, 26, 35 ili 48, navedeni retrovirus je γ-retrovirus ili lentivirus ili navedeni virus vakcinije je modificirana vakcinija Ankara (MVA).7. A vector containing a polynucleotide according to claim 6, optionally characterized in that:(a) said vector is an expression vector, optionally characterized in that said expression vector is a eukaryotic expression vector; or(b) said vector is a viral vector, optionally indicated that said viral vector is selected from the group consisting of adenovirus (Ad), retrovirus, poxvirus, adeno-associated virus, baculovirus, herpes simplex virus and vaccinia virus, optionally indicated that said the adenovirus is adenovirus serotype 5, 26, 35 or 48, said retrovirus is γ-retrovirus or lentivirus or said vaccinia virus is modified vaccinia Ankara (MVA).8. Izolirana stanica domaćina koja sadrži vektor prema patentnom zahtjevu 7, opcijski naznačena time, da:(a) navedena stanica domaćina je prokariotska stanica; ili(b) navedena stanica domaćina je eukariotska stanica, po mogućnosti naznačena time, da navedena eukariotska stanica je stanica sisavca, po mogućnosti naznačena time, da navedena stanica sisavca je stanica jajnika kineskog hrčka.8. An isolated host cell containing a vector according to claim 7, optionally characterized in that:(a) said host cell is a prokaryotic cell; or(b) said host cell is a eukaryotic cell, preferably indicated that said eukaryotic cell is a mammalian cell, preferably indicated that said mammalian cell is a Chinese hamster ovary cell.9. Metoda proizvodnje protutijela ili njegovog fragmenta koji veže antigen prema bilo kojem od patentnih zahtjeva 1 – 4 ili konstrukta prema patentnom zahtjevu 5, naznačena time, da navedena metoda uključuje ekspresiju polinukleotida koji kodira navedeno protutijelo, njegov fragment koji veže antigen ili konstrukt u stanici domaćina i dobivanje protutijela, njegovog fragmenta koji veže antigen ili konstrukta iz medija stanice domaćina.9. A method of producing an antibody or its antigen-binding fragment according to any of claims 1-4 or a construct according to claim 5, characterized in that said method includes the expression of a polynucleotide encoding said antibody, its antigen-binding fragment or construct in a cell of the host and obtaining the antibody, its antigen-binding fragment or construct from the medium of the host cell.10. Pripravak koji sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 – 4, konstrukt prema patentnom zahtjevu 5, polinukleotid prema patentnom zahtjevu 6, vektor prema patentnom zahtjevu 7 ili stanicu domaćina prema patentnom zahtjevu 8, za primjenu u:(I) liječenju poremećaja stanične proliferacije kod ljudi; opcijski naznačeno time, da:(a) navedeni poremećaj stanične proliferacije je rak odabran iz skupine koju čine leukemija, limfom, rak jetre, rak kostiju, rak pluća, rak mozga, rak mokraćnog mjehura, gastrointestinalni rak, rak dojke, rak srca, rak grlića maternice, rak maternice, rak glave i vrata, rak žučnog mjehura, rak grkljana, rak usne i usne šupljine, rak oka, melanom, rak gušterače, rak prostate, rak debelog crijeva, rak testisa i rak grla; ili(b) navedeni poremećaj stanične proliferacije je rak odabran iz skupine koju čine akutna limfoblastična leukemija (ALL), akutna mijeloična leukemija (AML), kronična limfocitna leukemija (CLL), kronična mijeloična leukemija (CML), adrenokortikalni karcinom, limfom povezan s AIDS-om, primarni limfom središnjeg živčanog sustava, rak anusa, rak slijepog crijeva, astrocitom, atipični teratoidni/rabdoidni tumor, karcinom bazalnih stanica, rak žučnih vodova, ekstrahepatični karcinom, obitelj Ewingovog sarkoma, osteosarkom i maligni fibrozni histiocitom, embrionalni tumori središnjeg živčanog sustava, tumori zametnih stanica središnjeg živčanog sustava, kraniofaringiomi, ependimomi, bronhijalni tumori, Burkittov limfom, karcinoidni tumor, primarni limfomi, hordomi, kronične mijeloproliferativne neoplazme, rak debelog crijeva, ekstrahepatični karcinom žučnih vodova, duktalni karcinom in situ (DCIS), rak endometrija, ependimom, rak jednjaka, estezioneuroblastom, ekstrakranijalni tumor zametnih stanica, ekstragonadalni tumor zametnih stanica, rak jajovoda, fibrozni histiocitom kosti, gastrointestinalni karcinoidni tumor, gastrointestinalni stromalni tumori (GIST), tumor zametnih stanica testisa, gestacijska trofoblastična bolest, gliom, pedijatrijski gliom moždanog debla, leukemija vlasastih stanica, hepatocelularni karcinom, histiocitoza Langerhansovih stanica, Hodgkinov limfom, hipofaringealni karcinom, tumori stanica otočića, neuroendokrini tumori gušterače, Wilmsov tumor i drugi tumori bubrega u djetinjstvu, histiocitoza Langerhansovih stanica, mikrocelularni karcinom pluća, kožni T-stanični limfom, intraokularni melanom, Merkel stanični karcinom, mezoteliom, metastatski skvamozni karcinom vrata, karcinom središnjeg trakta, sindromi višestruke endokrine neoplazije, multipli mijelom/neoplazma plazma stanica, mijelodisplastični sindromi, rak nosne šupljine i paranazalnog sinusa, nazofaringealni karcinom, neuroblastom, ne-Hodgkinov limfom (NHL), nemikrocelularni karcinom pluća (NSCLC), epitelni karcinom jajnika, rak jajnika zametnih stanica, rak jajnika s niskim malignim potencijalom, neuroendokrini tumori gušterače, papilomatoza, paragangliom, rak paranazalnog sinusa i nosne šupljine, rak paratiroidne žlijezde, rak penisa, rak ždrijela, feokromocitom, tumor hipofize, pleuropulmonalni blastom, primarni peritonealni karcinom, rak rektuma, retinoblastom, rabdomiosarkom, rak žlijezda slinovnica, Kaposijev sarkom, rabdomiosarkom, Sézaryjev sindrom, rak tankog crijeva, sarkom mekog tkiva, rak grla, timom i karcinom timusa, karcinom štitnjače, karcinom prijelaznih stanica bubrežne nakapnice i uretera, rak uretre, endometrijski rak maternice, sarkom maternice, vaginalni rak, rak vulve i Waldenströmova makroglobulinemija;(II) inhibiranju imunološkog odgovora posredovanog regulatornom T stanicom kod ljudi;ili(III) liječenju zarazne bolesti kod ljudi;opcijski naznačeno time, da navedenu zaraznu bolest uzrokuje jedan ili više agenasa odabranih iz grupe koju čine virus, bakterija, gljivica ili parazit;opcijski naznačeno time, da:(a) navedenu zaraznu bolest uzrokuje virus odabran iz skupine koju čine virus hepatitisa C, virus žute groznice, virus Kadam, virus bolesti šume Kyasanur, virus Langat, virus omske hemoragične groznice, virus Powassan, virus Royal Farm, virus Karshi , virus krpeljnog encefalitisa, Neudoerfl virus, Sofjin virus, Louping ill virus, Negishi virus, Meaban virus, Saumarez Reef virus, Tyuleniy virus, Aroa virus, denga virus, Kedougou virus, Cacipacore virus, Koutango virus, virus japanskog encefalitisa, virus Murray Valley encefalitisa, virus St. Louis encefalitisa, Usutu virus, virus Zapadnog Nila, Yaounde virus, Kokobera virus, Bagaza virus, Ilheus virus, virus izraelskog purećeg meningoencefalomijelitisa, Ntaya virus, Tembusu virus, Zika virus, Banzi virus, Bouboui virus, virus Edge Hill, virus Jugra, virus Saboya, virus Sepik, virus Uganda 5, virus Wesselsbron, virus žute groznice, virus Entebbe šišmiša, virus Yokose, virus Apoi, virus Cowbone Ridge, virus Jutiapa, virus Modoc, virus Sal Vieja, San Perlita virus, virus Bukalasa šišmiša, Carey Island virus, virus Dakar šišmiša, Montana myotis leukoencephalitis virus, virus Phnom Penh šišmiša, Rio Bravo virus, virus Tamana šišmiša, virus agensa spajanja stanica, Ippy virus, Lassa virus, virus limfocitnog koriomeningitisa (LCMV), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Paraná virus, Pichinde virus, Pirital virus, sabiá virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, Chapare virus, Lujo virus, Hantaan virus, Sin Nombre virus, Dugbe virus, Bunyamwera virus, virus Rift Valley groznice, La Crosse virus, virus kalifornijskog encefalitisa, virus krimsko-kongoanske hemoragijske groznice (CCHF), virus ebole, virus Marburg, virus venecuelanskog konjskog encefalitisa (VEE), virus istočnog konjskog encefalitisa (EEE), virus zapadnog konjskog encefalitisa (WEE), virus Sindbis, virus rubeole, virus šume Semliki, virus rijeke Ross, virus šume Barmah, virus O'nyong'nyong i chikungunya virus, virus malih boginja, virus majmunskih boginja, vakcinija virus, herpes simplex virus, humani herpes virus, citomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus, herpes virus povezan s Kaposijevim sarkomom (KSHV), virus influence, virus teškog akutnog respiratornog sindroma (SARS), virus bjesnoće, virus vezikularnog stomatitisa (VSV), humani respiratorni sincicijski virus (RSV), virus newcastleske bolesti, hendravirus, nipahvirus, virus ospica, virus goveđe kuge, virus pseće kuge, Sendai virus, virus humane parainfluence (npr. 1, 2, 3 i 4), rinovirus, virus zaušnjaka, poliovirus, ljudski enterovirus (A, B, C i D), virus hepatitisa A, coxsackie virus, virus hepatitisa B, humani papiloma virus, adeno-povezan virus, astrovirus, JC virus, BK virus, SV40 virus, Norwalk virus, rotavirus, virus humane imunodeficijencije (HIV) i ljudski T-limfotropni virus tipa I i II;(b) navedenu zaraznu bolest uzrokuje bakterija koja pripada rodu odabranom iz skupine koju čine Salmonella, Streptococcus, Bacillus, Listeria, Corynebacterium, Nocardia, Neisseria, Actinobacter, Moraxella, Enterobacteriacece, Pseudomonas, Escherichia, Klebsiella, Serratia, Enterobacter, Proteus, Salmonella, Shigella, Yersinia, Haemophilus, Bordatella, Legionella, Pasturella, Francisella, Brucella, Bartonella, Clostridium, Vibrio, Campylobacter i Staphylococcus;(c) navedenu zaraznu bolest uzrokuje gljivica odabrana iz skupine koju čine Aspergillus, Candida, Malassezia, Trichosporon, Fusarium, Acremonium, Rhizopus, Mucor, Pneumocystis i Absidia; ili(d) navedenu zaraznu bolest uzrokuje parazit odabran iz skupine koju čine Entamoeba hystolytica, Giardia lamblia, Cryptosporidium muris, Trypanosomatida gambiense, Trypanosomatida rhodesiense, Trypanosomatida crusi, Leishmania mexicana, Leishmania braziliensis, Leishmania tropica, Leishmania donovani, Tox oplazma gondii, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, Trichomonas vaginalis i Histomonas meleagridis. Primjeri helminti parazita uključuju richuris trichiura, Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Wuchereria bancrofti i Dracunculus medinensis, Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, Fasciola hepati ca, Fasciola gigantica, Heterophyes, Paragonimus westermani, Taenia solium, Taenia saginata, Hymenolepis nana i Echinococcus granulosus.10. A preparation containing an antibody or an antigen-binding fragment thereof according to any of claims 1-4, a construct according to claim 5, a polynucleotide according to claim 6, a vector according to claim 7 or a host cell according to claim 8, for use in :(I) treatment of cell proliferation disorders in humans; optionally indicated that:(a) said cell proliferation disorder is a cancer selected from the group consisting of leukemia, lymphoma, liver cancer, bone cancer, lung cancer, brain cancer, bladder cancer, gastrointestinal cancer, breast cancer, heart cancer, cervical cancer, uterine cancer, head and neck cancer, gallbladder cancer, larynx cancer, lip and oral cavity cancer, eye cancer, melanoma, pancreatic cancer, prostate cancer, colon cancer, testicular cancer and throat cancer; or(b) said cell proliferation disorder is a cancer selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), adrenocortical carcinoma, AIDS-related lymphoma- om, primary lymphoma of the central nervous system, cancer of the anus, cancer of the appendix, astrocytoma, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, extrahepatic carcinoma, Ewing's sarcoma family, osteosarcoma and malignant fibrous histiocytoma, embryonal tumors of the central nervous system, germ cell tumors of the central nervous system, craniopharyngiomas, ependymomas, bronchial tumors, Burkitt's lymphoma, carcinoid tumor, primary lymphomas, chordomas, chronic myeloproliferative neoplasms, colon cancer, extrahepatic bile duct carcinoma, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma , esophageal cancer, aesthesioneuroblastoma, extracranial germ cell tumor, extragonadal germ cell tumor, fallopian tube cancer, fibrous histiocytoma of bone, gastrointestinal carcinoid tumor, gastrointestinal stromal tumors (GIST), testicular germ cell tumor, gestational trophoblastic disease, glioma, pediatric brainstem glioma, hairy cell leukemia, hepatocellular carcinoma, Langerhans cell histiocytosis, Hodgkin's lymphoma, hypopharyngeal carcinoma, islet cell tumors, pancreatic neuroendocrine tumors, Wilms tumor and other childhood kidney tumors, Langerhans cell histiocytosis, small cell lung carcinoma, cutaneous T-cell lymphoma, intraocular melanoma , Merkel cell carcinoma, mesothelioma, metastatic squamous cell carcinoma of the neck, central tract carcinoma, multiple endocrine neoplasia syndromes, multiple myeloma/plasma cell neoplasm, myelodysplastic syndromes, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma (NHL) , non-small cell lung cancer (NSCLC), epithelial ovarian cancer, germ cell ovarian cancer, low-grade ovarian cancer, pancreatic neuroendocrine tumors, papillomatosis, paraganglioma, paranasal sinus and nasal cavity cancer, parathyroid gland cancer, penile cancer, pharyngeal cancer, pheochromocytoma , pituitary tumor, pleuropulmonary blastoma, primary peritoneal carcinoma, rectal cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Kaposi's sarcoma, rhabdomyosarcoma, Sézary syndrome, small bowel cancer, soft tissue sarcoma, throat cancer, thymoma and thymic carcinoma, thyroid carcinoma, carcinoma transitional cells of the renal tubule and ureter, urethral cancer, uterine endometrial cancer, uterine sarcoma, vaginal cancer, vulvar cancer and Waldenström's macroglobulinemia;(II) inhibiting the regulatory T cell-mediated immune response in humans;or(III) treating an infectious disease in humans;optionally indicated that said infectious disease is caused by one or more agents selected from the group consisting of virus, bacteria, fungus or parasite;optionally indicated that:(a) said infectious disease is caused by a virus selected from the group consisting of hepatitis C virus, yellow fever virus, Kadam virus, Kyasanur forest disease virus, Langat virus, Ohm haemorrhagic fever virus, Powassan virus, Royal Farm virus, Karshi virus, tick-borne encephalitis virus , Neudoerfl virus, Sofjin virus, Louping ill virus, Negishi virus, Meaban virus, Saumarez Reef virus, Tyuleniy virus, Aroa virus, dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St . Louis encephalitis, Usutu virus, West Nile virus, Yaounde virus, Kokobera virus, Bagaza virus, Ilheus virus, Israeli turkey meningoencephalomyelitis virus, Ntaya virus, Tembusu virus, Zika virus, Banzi virus, Bouboui virus, Edge Hill virus, Jugra virus, Saboya, Sepik virus, Uganda 5 virus, Wesselsbron virus, Yellow fever virus, Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa bat virus, Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitis virus, Phnom Penh bat virus, Rio Bravo virus, Tamana bat virus, Cell fusion agent virus, Ippy virus, Lassa virus, Lymphocytic choriomeningitis virus (LCMV), Mobala virus, Mopeia virus, Amapari virus , Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Oliveros virus, Paraná virus, Pichinde virus, Pirital virus, sabiá virus, Tacaribe virus, Tamiami virus, Whitewater Arroyo virus, Chapare virus, Lujo virus, Hantaan virus, Sin Nombre virus, Dugbe virus, Bunyamwera virus, Rift Valley fever virus, La Crosse virus, California encephalitis virus, Crimean-Congo hemorrhagic fever (CCHF) virus, Ebola virus, Marburg virus, Venezuelan equine encephalitis virus (VEE), Eastern equine virus encephalitis (EEE), western equine encephalitis (WEE) virus, Sindbis virus, rubella virus, Semliki forest virus, Ross River virus, Barmah forest virus, O'nyong'nyong virus and chikungunya virus, measles virus, monkey pox virus, vaccinia virus, herpes simplex virus, human herpes virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), Varicella-Zoster virus, Kaposi's sarcoma-associated herpes virus (KSHV), influenza virus, severe acute respiratory syndrome virus (SARS), rabies virus, vesicular stomatitis virus (VSV), human respiratory syncytial virus (RSV), Newcastle disease virus, hendravirus, nipahvirus, measles virus, rinderpest virus, canine distemper virus, Sendai virus, human parainfluenza virus (eg 1, 2, 3 and 4), rhinovirus, mumps virus, poliovirus, human enterovirus (A, B, C and D), hepatitis A virus, coxsackie virus, hepatitis B virus, human papilloma virus, adeno-associated virus, astrovirus, JC virus, BK virus, SV40 virus, Norwalk virus, rotavirus, human immunodeficiency virus (HIV), and human T-lymphotropic virus types I and II;(b) the said infectious disease is caused by a bacterium belonging to a genus selected from the group consisting of Salmonella, Streptococcus, Bacillus, Listeria, Corynebacterium, Nocardia, Neisseria, Actinobacter, Moraxella, Enterobacteriacece, Pseudomonas, Escherichia, Klebsiella, Serratia, Enterobacter, Proteus, Salmonella, Shigella, Yersinia, Haemophilus, Bordatella, Legionella, Pasturella, Francisella, Brucella, Bartonella, Clostridium, Vibrio, Campylobacter and Staphylococcus;(c) said infectious disease is caused by a fungus selected from the group consisting of Aspergillus, Candida, Malassezia, Trichosporon, Fusarium, Acremonium, Rhizopus, Mucor, Pneumocystis and Absidia; or(d) said infectious disease is caused by a parasite selected from the group consisting of Entamoeba hystolytica, Giardia lamblia, Cryptosporidium muris, Trypanosomatida gambiense, Trypanosomatida rhodesiense, Trypanosomatida crusi, Leishmania mexicana, Leishmania braziliensis, Leishmania tropica, Leishmania donovani, Tox oplazma gondii, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium falciparum, Trichomonas vaginalis and Histomonas meleagridis. Examples of helminth parasites include richuris trichiura, Ascaris lumbricoides, Enterobius vermicularis, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Wuchereria bancrofti and Dracunculus medinensis, Schistosoma mansoni, Schistosoma haematobium, Schistosoma japonicum, Fasciola hepati ca, Fasciola gigantica, Heterophyes, Paragonimus westermani, Taenia solium, Taenia saginata, Hymenolepis nana and Echinococcus granulosus.11. Komplet koji sadrži sredstvo odabrano iz skupine koja se sastoji od protutijela ili njegovog fragmenta koji veže antigen prema bilo kojem od patentnih zahtjeva 1 – 4, konstrukta prema patentnom zahtjevu 5, polinukleotida prema patentnom zahtjevu 6, vektora prema patentnom zahtjevu 7 ili stanice domaćina prema patentnom zahtjevu 8; opcijski naznačen time, da navedeni komplet dodatno sadrži:(a) upute za transfekciju navedenog vektora u stanicu domaćina;(b) upute za ekspresiju navedenog protutijela, njegovog fragmenta koji veže antigen ili konstrukta u navedenoj stanici domaćina;(c) reagens koji se može koristiti za ekspresiju protutijela, njegovog fragmenta koji veže antigen, jednolančanog polipeptida ili konstrukta u navedenoj stanici domaćina;(d) upute za davanje navedenog sredstva ljudskom pacijentu; ili(e) upute za izradu ili primjenu navedenog sredstva.11. Kit containing an agent selected from the group consisting of an antibody or an antigen-binding fragment thereof according to any one of claims 1-4, a construct according to claim 5, a polynucleotide according to claim 6, a vector according to claim 7 or a host cell according to patent claim 8; optionally indicated by the fact that the specified kit additionally contains:(a) instructions for transfection of said vector into a host cell;(b) instructions for expressing said antibody, antigen-binding fragment thereof or construct in said host cell;(c) a reagent that can be used to express the antibody, antigen-binding fragment thereof, single-chain polypeptide or construct in said host cell;(d) instructions for administering said agent to a human patient; or(e) instructions for the production or application of the specified means.